Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926930 | 0.89 | TSHR (0.51) | MAPTTP53LMNASCN9AGLO1 | |
| SCHEMBL6927666 | 0.83 | CBFB (0.54) | MAPTTP53LMNAGLO1 | |
| SCHEMBL6924680 | 0.82 | GRM4 (0.49) | MAPTTP53LMNASCN9AGLO1 | |
| SCHEMBL6926267 | 0.81 | MAPT (0.51) | MAPTTP53LMNAMOGAT2TSHR | |
| SCHEMBL6926524 | 0.81 | MAPT (0.68) | MAPTTP53LMNAPOLBMMP2 | |
| SCHEMBL6925826 | 0.78 | MAPT (0.49) | MAPTTP53LMNAGLO1POLB | |
| SCHEMBL11369844 | 0.77 | MAPT (0.46) | MAPTTP53LMNAPOLBTDP1 | |
| SCHEMBL11370367 | 0.77 | MAPT (0.48) | MAPTTP53LMNAGLO1POLB | |
| SCHEMBL6926724 | 0.73 | CBFB (0.55) | MAPTTP53LMNAGLO1TDP1 | |
| SCHEMBL6926782 | 0.70 | MAPT (0.66) | MAPTTP53LMNAMMP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184556-A1 | SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-19 | — | — | US | disclosed |
| US-20120184556-A1 | SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-19 | — | — | US | disclosed |
| WO-2011011722-A1 | SUBSTITUTED BENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | VANDERBILT UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184556-A1 | SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS | GRM4, GRIK4, GRIA4 | MAPT 3868/4885TP53 4875/4885LMNA 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.